Perspective Therapeutics (CATX) vs Viemed Healthcare (VMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Viemed Healthcare (VMD) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 38.6% versus a loss of 31.1%. Over five years, VMD leads with a +65.0% price change compared with -57.1% for CATX. Viemed Healthcare is the larger company by market cap ($362.6 million vs $303.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | VMD |
|---|---|---|
| Share price | $2.66 | $9.52 |
| Market cap | $303.64M | $362.60M |
| 1-day change | -1.85% | +1.17% |
| YTD return | -3.27% | +28.13% |
| 1-year return | -31.09% | +38.57% |
| 5-year return | -57.10% | +64.99% |
| P/E ratio (TTM) | — | 26.44 |
| Forward P/E | — | 23.80 |
| EPS (TTM) | $-1.33 | $0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $12.61 |
| 52-week low | $1.96 | $6.05 |
| Distance from 52-week high | -56.82% | -24.50% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +362.03% | +31.30% |
| Average volume | 1.65M | 356.46K |
| Shares outstanding | 114.15M | 38.09M |
| Employees | 163 | 1,438 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VMD has outperformed CATX by 69.7 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Viemed Healthcare
VMD stock →Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
Health Care · Misc Health and Biotechnology Services · 1,438 employees
CATX vs VMD FAQ
Which is bigger, Perspective Therapeutics or Viemed Healthcare?
Viemed Healthcare (VMD) is larger, with a market capitalization of $362.60M compared with $303.64M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or VMD?
VMD returned +38.57% over the past 12 months, compared with -31.09% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Viemed Healthcare in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Perspective Therapeutics and Misc Health and Biotechnology Services for Viemed Healthcare.